JANÍKOVÁ, Andrea, Renata CHLOUPKOVÁ, Vit CAMPR, Pavel KLENER, Jitka HAMOUZOVA, David BELADA, Vit PROCHAZKA, Robert PYTLIK, Jan PIRNOS, Juraj DURAS, Heidi MOCIKOVA, Zbyněk BORTLÍČEK, Natasa KOPALOVA, Jiří MAYER and Marek TRNENY. First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients. Annals of hematology. New York: Springer Verlag, 2019, vol. 98, No 8, p. 1961-1972. ISSN 0939-5555. Available from: https://dx.doi.org/10.1007/s00277-019-03694-y.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients
Authors JANÍKOVÁ, Andrea (203 Czech Republic, guarantor, belonging to the institution), Renata CHLOUPKOVÁ (203 Czech Republic, belonging to the institution), Vit CAMPR (203 Czech Republic), Pavel KLENER (203 Czech Republic), Jitka HAMOUZOVA (203 Czech Republic), David BELADA (203 Czech Republic), Vit PROCHAZKA (203 Czech Republic), Robert PYTLIK (203 Czech Republic), Jan PIRNOS (203 Czech Republic), Juraj DURAS (203 Czech Republic), Heidi MOCIKOVA (203 Czech Republic), Zbyněk BORTLÍČEK (203 Czech Republic, belonging to the institution), Natasa KOPALOVA (203 Czech Republic), Jiří MAYER (203 Czech Republic, belonging to the institution) and Marek TRNENY (203 Czech Republic).
Edition Annals of hematology, New York, Springer Verlag, 2019, 0939-5555.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30205 Hematology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 2.904
RIV identification code RIV/00216224:14110/19:00112767
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1007/s00277-019-03694-y
UT WoS 000475694100018
Keywords in English T cell lymphoma; Auto-SCT; Etoposide; Prognosis
Tags 14110212, 14119612, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 11/5/2020 13:26.
Abstract
Peripheral T cell lymphomas (PTLs) have a globally poor prognosis. The CHOP regimen shows insufficient efficacy; first-line consolidation with autologous stem cell transplantation (auto-SCT) is a promising strategy but has never been confirmed by randomized data. We analyzed retrospectively 906 patients diagnosed with PTL between 1999 and 2015. Chemotherapy was given to 862 patients, and 412 of them were <60years. In this subset, we compared induction with CHOP (n=113) vs. CHOEP (n=68) and tested auto-SCT (n=79) vs. no SCT (n=73) in the intent-to-treat analysis. The median age of the whole cohort at diagnosis was 60years (range; 18-91); the median follow-up was 4.3years (range; 0.1-17.8). A shorter overall survival (OS) was associated with the male gender, age >= 60years, stage III/IV, performance status >= 2, bulky tumor >= 10cm, and elevated LDH. CHOEP induction showed a better 5-year PFS (25.0% vs. 32.9%; p.001), and 5-year OS (65.6% vs. 47.6%; p.008) than CHOP. Auto-SCT compared to no SCT brought a 5-year OS of 49.2% vs. 59.5% (p.187). Auto-SCT did not influence the OS in low-risk or low-intermediate risk PTLs. The high-intermediate and high-risk IPIs displayed a worse 5-year OS in auto-SCT arm (17.7% vs.46.2%; p.049); however, 73.9% of the patients never received planned auto-SCT. Our population-based analysis showed the superiority of CHOEP over CHOP in first-line treatment. We confirm the 5-year OS of around 50% in PTLs undergoing auto-SCT. However, the intended auto-SCT could not be given in 73.9% of the high-risk PTLs.
PrintDisplayed: 15/7/2024 09:26